Survival in triple negative metastatic breast carcinoma

  • Aleksandar Nikola Serafimov Clinical Hospital Stip University of Goce Delcev Stip, Macedonia
  • Marija A Karakolevska-Ilova
  • Elena S. Simeonovska Joveva
Keywords: Breast Cancer, Metastases, Hormone Therapy, Immunohistochemistry


Breast cancer is the most common non-skin malignancy in women, the second most common cause of cancer death, and the main cause of death in women ages 45 to 55 years. An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Approximately 5-10% of patients with breast cancer have distant metastases at first presentation.The patient came to the Clinic of oncology and radiotherapy in March 2005 for further treatment with the diagnosis: Carcinoma metastaticum vertebrae lumbosacralis.Initial treatment was included 6 cycles of chemotherapy, bisphosphonate therapy and realized radiotherapy. Tumor markers at the end of treatment: CEA 238; CA15-3: 19.6.  After that a radical mastectomy of the left breast with dissection of left axilla was conducted and pathological analysis showed poorly differentiated ductal invasive carcinoma (grade 3 according to Nottingham Histologic Score) with immunohistochemistry findings: HER: negative, ER: negative, PR: negative or Triple negative breast cancer (TNBC).

Author Biography

Aleksandar Nikola Serafimov, Clinical Hospital Stip University of Goce Delcev Stip, Macedonia
Medical doctor at department of is my second email.


1. Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996 May; 14(5):1558-64.

2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17;366(9503):2087-106.

3. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. N Engl J Med 2002; 347:1233-1241.

4. Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw. 2003 Apr; 1(2):189-96.

5. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005 Aug 6-12;366(9484):455-62

6. Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011 Sep;47 Suppl 3:S6-22
Case Reports